212 related articles for article (PubMed ID: 31930974)
1. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.
Polyzos SA; Kountouras J; Mantzoros CS
Metabolism; 2020 Mar; 104():154144. PubMed ID: 31930974
[No Abstract] [Full Text] [Related]
2. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
Venetsanaki V; Karabouta Z; Polyzos SA
Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
Makri E; Cholongitas E; Tziomalos K
World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
[TBL] [Abstract][Full Text] [Related]
4. Is obeticholic Acid the solution to nonalcoholic steatohepatitis?
Wong VW; Wong GL; Chan FK
Gastroenterology; 2015 Apr; 148(4):851-2. PubMed ID: 25726736
[No Abstract] [Full Text] [Related]
5. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Neuschwander-Tetri BA; Loomba R; Sanyal AJ; Lavine JE; Van Natta ML; Abdelmalek MF; Chalasani N; Dasarathy S; Diehl AM; Hameed B; Kowdley KV; McCullough A; Terrault N; Clark JM; Tonascia J; Brunt EM; Kleiner DE; Doo E;
Lancet; 2015 Mar; 385(9972):956-65. PubMed ID: 25468160
[TBL] [Abstract][Full Text] [Related]
6. Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.
Musso G
Hepatology; 2015 Jun; 61(6):2104-6. PubMed ID: 25753820
[No Abstract] [Full Text] [Related]
7. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
Loomba R; Sanyal AJ; Kowdley KV; Terrault N; Chalasani NP; Abdelmalek MF; McCullough AJ; Shringarpure R; Ferguson B; Lee L; Chen J; Liberman A; Shapiro D; Neuschwander-Tetri BA
Gastroenterology; 2019 Jan; 156(1):88-95.e5. PubMed ID: 30222962
[TBL] [Abstract][Full Text] [Related]
8. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
[TBL] [Abstract][Full Text] [Related]
9. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Gawrieh S; Chalasani N
Clin Liver Dis; 2018 Feb; 22(1):189-199. PubMed ID: 29128056
[TBL] [Abstract][Full Text] [Related]
10. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
Adorini L; Pruzanski M; Shapiro D
Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
[TBL] [Abstract][Full Text] [Related]
11. Trials of obeticholic acid for non-alcoholic steatohepatitis.
Armstrong MJ; Newsome PN
Lancet; 2015 Jul; 386(9988):28. PubMed ID: 26169862
[No Abstract] [Full Text] [Related]
12. Trials of obeticholic acid for non-alcoholic steatohepatitis.
Musso G; Cassader M; Gambino R
Lancet; 2015 Jul; 386(9988):27. PubMed ID: 26169860
[No Abstract] [Full Text] [Related]
13. Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
Sanyal AJ
Dig Dis; 2015; 33(3):426-32. PubMed ID: 26045279
[TBL] [Abstract][Full Text] [Related]
14. Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply.
Neuschwander-Tetri BA; Van Natta ML; Tonascia J; Brunt EM; Kleiner DE
Lancet; 2015 Jul; 386(9988):28-29. PubMed ID: 26169861
[No Abstract] [Full Text] [Related]
15. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives.
Gitto S; Guarneri V; Sartini A; Andreone P
Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):165-171. PubMed ID: 29082798
[TBL] [Abstract][Full Text] [Related]
16. Obeticholic acid for the treatment of nonalcoholic steatohepatitis.
Shah RA; Kowdley KV
Expert Rev Gastroenterol Hepatol; 2020 May; 14(5):311-321. PubMed ID: 32241197
[TBL] [Abstract][Full Text] [Related]
17. NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more?
Ray K
Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):1. PubMed ID: 25421586
[No Abstract] [Full Text] [Related]
18. Obeticholic acid: expanding the therapeutic landscape of NASH.
Arrese M; Cabrera D; Barrera F
Ann Hepatol; 2015; 14(3):430-2. PubMed ID: 25864227
[No Abstract] [Full Text] [Related]
19. [Treatment Options in Non-alcoholic Fatty Liver Disease].
Kim W
Korean J Gastroenterol; 2017 Jun; 69(6):353-358. PubMed ID: 28637104
[TBL] [Abstract][Full Text] [Related]
20. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
